Cowen Upgrades Myriad Genetics (MYGN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Cowen Upgrades Myriad Genetics (MYGN) to Outperform
January 4, 2019 10:05 AM EST
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the publication of the landmark GeneSight GUIDED study in the Journal of Psychiatric Research. The study is the first-ever prospective, large-scale, blinded, randomized controlled trial evaluating combinatorial pharmacogenomics testing in 1,167 patients with treatment-resistant major depressive disorder who had failed at least one psychotropic medication.
The publication of the GUIDED study represents a major milestone for Myriad and a significant... More
January 2, 2019 4:18 PM EST
Needham & Company analyst Stephen Unger initiates coverage on Myriad Genetics (NASDAQ: MYGN) with a Strong Buy rating and a price target of $36.00.
The analyst commented, "We believe Myriad Genetics has significant potential for ongoing EPS upside from an expanding portfolio of molecular... More
